Log in
Enquire now
Cygnal Therapeutics

Cygnal Therapeutics

Cygnal Therapeutics is an exoneural biology company.

OverviewStructured DataIssuesContributors

Contents

cygnaltx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Biotechnology
Biotechnology
‌
Synthetic chemistry
Engineering
Engineering
Healthcare
Healthcare
Therapeutics
Therapeutics
Biopharmaceutical
Biopharmaceutical
...
Location
United States
United States
Cambridge, Massachusetts
Cambridge, Massachusetts
B2X
B2B
B2B
CEO
Pearl Huang
Pearl Huang
Founder
Jordi Mata-Fink
Jordi Mata-Fink
Avak Kahvejian
Avak Kahvejian
Date Incorporated
2016
Number of Employees (Ranges)
11 – 50
Email Address
info@sonatatx.com
Full Address
325 VASSAR STREET CAMBRIDGE, 02139 MA USA
Investors
Flagship Pioneering
Flagship Pioneering
Founded Date
January 1, 2016
Total Funding Amount (USD)
65,000,000
Latest Funding Round Date
October 2019
Country
United States
United States

Other attributes

Company Operating Status
Active
Wikidata ID
Q104481196

Cygnal Therapeutics a developing company with focus in drugs in the field of exoneural biology. The company's platform combines six core technological and scientific components to reveal new insights into disease.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Cygnal Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.